



## King's Research Portal

*Document Version*  
Peer reviewed version

[Link to publication record in King's Research Portal](#)

*Citation for published version (APA):*

Himmerich, H., Willmund, G. D., Zimmermann, P., Wolf, J.-E., Bühler, A. H., Kirkby, K. C., Dalton, B., Holdt, L. M., Teupser, D., & Wesemann, U. (2016). Serum concentrations of TNF- $\alpha$  and its soluble receptors during psychotherapy in German soldiers suffering from combat-related PTSD. *Psychiatria Danubina*, 28(3), 293-298. [http://www.hdbp.org/psychiatria\\_danubina/2016\\_Vol\\_28\\_No\\_3.html?ver=1.1](http://www.hdbp.org/psychiatria_danubina/2016_Vol_28_No_3.html?ver=1.1)

### **Citing this paper**

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

### **General rights**

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

### **Take down policy**

If you believe that this document breaches copyright please contact [librarypure@kcl.ac.uk](mailto:librarypure@kcl.ac.uk) providing details, and we will remove access to the work immediately and investigate your claim.

# **Serum concentrations of TNF- $\alpha$ and its soluble receptors during psychotherapy in German soldiers suffering from combat-related PTSD**

(Short title: TNF- $\alpha$  and sTNF-R levels during psychotherapy for PTSD)

Hubertus Himmerich<sup>1,2#</sup>, Gerd D. Willmund<sup>1</sup>, Peter Zimmermann<sup>1</sup>, Jörg-Egbert Wolf<sup>1</sup>, Antje H. Bühler<sup>1</sup>, Kenneth C. Kirkby<sup>3</sup>, Bethan Dalton<sup>2</sup>, Lesca M. Holdt<sup>4</sup>, Daniel Teupser<sup>4</sup>, Ulrich Wesemann<sup>1</sup>

<sup>1</sup> Department of Psychiatry, Psychotherapy and Psychotraumatology, Bundeswehr Hospital, Berlin, Germany

<sup>2</sup> Department of Psychological Medicine, King's College London, London, UK

<sup>3</sup> Department of Psychiatry, University of Tasmania, Hobart, Australia

<sup>4</sup> Institute of Laboratory Medicine, Ludwig-Maximilians-University Munich, Munich, Germany

## **Brief Report**

Revised manuscript re-submitted to:

### **Psychiatria Danubina**

# Corresponding author: Dr. Hubertus Himmerich, Department of Psychological Medicine, King's College London, 103 Denmark Hill, London SE5 8AF, UK, Fax: +44-2078480182, Email: hubertus.himmerich@kcl.ac.uk

#### **Key words:**

Cytokines, tumor necrosis factor (TNF)-alpha, soluble TNF receptors, post-traumatic stress disorder, psychotherapy

## **Abstract**

**Background:** Changes in serum concentrations of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and its soluble receptors (sTNF-R) p55 and p75 have been shown to be associated with various psychiatric treatments.

**Methods:** Before and after treatment, serum levels of TNF- $\alpha$ , sTNF-R p55 and sTNF-R p75 were measured in 38 German soldiers who had been deployed abroad and suffered from combat-related post-traumatic stress disorder (PTSD). Patients were randomized either to inpatient psychotherapy (N=21) including eye movement desensitization and reprocessing (EMDR) or to outpatient clinical management (N=17). Symptoms of PTSD were measured using the Post-traumatic Stress Diagnostic Scale (PDS).

**Results:** The PDS score significantly decreased across time in both groups. Serum concentrations of TNF- $\alpha$  increased, while sTNF-R p55 and sTNF-R p75 levels decreased significantly. After the treatment period, we could not detect any significant difference regarding TNF- $\alpha$ , sTNF-R p55 or sTNF-R p75 levels between the inpatient psychotherapy group and the outpatient clinical management control group.

**Discussion:** This relatively small clinical study suggests that specific inpatient psychotherapy but also non-specific supportive outpatient treatment for PTSD are associated with changes in the TNF- $\alpha$  system. This may represent an immunological effect or side effect of psychotherapy.

## Introduction

In recent years, cytokines, which are messenger molecules of the immune system, have received increasing attention in psychiatric research (Borovcanin et al. 2012, Borovcanin et al. 2013, Maes et al. 2012, Müller et al. 2015) as they can influence various types of brain cells and their connectivity, the production and metabolism of neurotransmitters, and neuroendocrine systems (Miller et al. 2013). One cytokine that has been the subject of much scientific interest among researchers is tumor necrosis factor (TNF)- $\alpha$  (Berthold-Losleben & Himmerich 2008). It acts via two different receptors which can be cleaved from the surface of different types of cells and are measurable in the serum as soluble TNF- $\alpha$  receptors sTNF-R p55 and sTNF-R p75.

TNF- $\alpha$  is a glycoprotein hormone which was isolated as a soluble factor released by host cells that caused necrosis of a transplanted tumor (Carswell et al. 1975). It is released by monocytes, macrophages and other white blood cells, the endothelium, fatty tissue and several other body tissues and is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. TNF- $\alpha$  has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance and cancer (Ghezzi & Cerami 2005).

Changes in the TNF- $\alpha$  system have been shown to be associated with a number of psychiatric disorders such as schizophrenia (Pandey et al. 2015, Turhan et al. 2016) and depression (Himmerich et al. 2008; Schmidt et al. 2014). However, in post-traumatic stress disorder (PTSD), results are inconsistent; some studies report increased production of TNF- $\alpha$  in patients suffering from PTSD (Chen et al. 2014; Lindqvist et al. 2014), others do not (Himmerich et al. 2015, Himmerich et al. 2016, Jergović et al. 2015).

In addition to psychiatric disorders *per se*, psychopharmacological treatments such as antidepressants (Kraus et al. 2002, Munzer et al. 2013), mood stabilizers (Himmerich et al. 2005, Himmerich et al. 2013) and antipsychotics (Himmerich et al. 2011; Kluge et al. 2009) have been shown to lead to changes in the TNF- $\alpha$  system, most often to an increase in plasma levels of TNF- $\alpha$  and its receptors. However, an increase of TNF- $\alpha$  production during therapy is not generally conceived as a favorable effect, as TNF- $\alpha$  is an inflammatory marker that has been shown to be associated with psychiatric disorders such as schizophrenia (Pandey et al. 2015, Turhan et al. 2016) and depression (Berthold-Losleben & Himmerich 2008; Himmerich

et al. 2008; Schmidt et al. 2014). Moreover, animal studies have shown that TNF- $\alpha$  production increases during stressful events such as social isolation (Krügel et al. 2014).

The effect of psychological therapies on TNF- $\alpha$  levels is less clear. Studies indicate that dynamic psychotherapy (Del Grande da Silva et al. 2016) and cognitive behavior therapy, but not narrative cognitive therapy (Moreira et al. 2015), may lead to decreased TNF- $\alpha$  production in depressed patients. To our knowledge, the effect of psychotherapy for PTSD on serum levels of TNF- $\alpha$  or its receptors has never been reported. To investigate this, we measured these parameters in soldiers with combat-related PTSD before and after treatment.

## Methods

Participants: In a cross-sectional study we examined 135 male German soldiers, 38 of whom had served deployments abroad and were diagnosed with combat-related PTSD according to ICD-10 criteria as a consequence of their deployments (Himmerich et al. 2015, Himmerich et al. 2016). To be included into this study, the deployment with the event leading to PTSD had to be no more than 24 months ago.

For the present longitudinal investigation, the 38 patients with PTSD were randomly allocated to six weeks of either immediate inpatient psychotherapy (N=21) or outpatient clinical management control group (N=17). The latter patients were placed on a waiting list for later inpatient psychotherapy.

Treatment conditions: Inpatient psychotherapy comprised of 6 weeks of treatment on a specialized ward within the Department of Psychiatry, Psychotherapy and Psychotraumatology at the Bundeswehr Hospital in Berlin, Germany. The treatment package included individual eye movement desensitization and reprocessing (EMDR) treatment as well as psychotherapeutic groups, physiotherapy, occupational and art therapy. Outpatient clinical management included less structured supportive psychological therapy sessions. This group did not receive EMDR treatment. Both patient groups were allowed psychopharmacological treatments as determined by the doctor and patient, without interference.

Psychological measures: PTSD symptomatology was measured using the Post-traumatic Stress Diagnostic Scale (PDS) German version at baseline (at inpatient admission or allocation to clinical outpatient management) and after treatment (at discharge or after six weeks of outpatient treatment). The PDS was developed and validated by Foa et al. (Foa et al. 1995) to provide a reliable self-report measure of PTSD. Its questions relate to the frequency of distressing and intrusive thoughts, posttraumatic avoidance and hyperarousal. The PDS has been shown to have high reliability and validity in measuring PTSD symptoms (McCarthy et al. 2008).

Cytokine measurement: After blood drawing at baseline and after treatment, serum probes were immediately centrifuged at 3000 rpm for 10 min. The supernatant was aliquoted and stored in non-absorbing polypropylene tubes of 300 µl. Probes were shock-frozen in liquid nitrogen and stored in freezers at -80 °C until further measurement. TNF- $\alpha$  and its soluble

receptors sTNF-R p55 and p75 were measured in the serum using a Bio-Plex Pro™ human cytokine immunoassay from Bio Rad, Germany. An implausible outlier of TNF- $\alpha$  > 100 pg/ml (n=1) was excluded from the analysis.

Statistics: Repeated measures ANOVAs (group: inpatient psychotherapy; outpatient control) x (time: baseline; post-treatment) were used to examine effects of treatment condition on the dependent measures of PDS and cytokine levels. Concurrent medication was dichotomized into two groups, those receiving antidepressants and those receiving homeopathic or no medication, and analyzed by repeated measures ANOVAs (Medication: on antidepressants; not on antidepressants) x (time: baseline; post-treatment) for TNF- $\alpha$  and its soluble receptors. All statistical tests were performed using SPSS 21. As this was a pilot study, we accepted an uncorrected p-value of  $p \leq .05$  as an indicator of statistical significance.

Ethics: The study was approved by the local ethics committee (Ethikausschuss Charité, application number: EA1/270/11).

## Results

Psychosocial group characteristics: Mean age of the whole study sample (including the inpatient and outpatient treatment groups) was 28.5 ( $\pm 5.6$ ) years, and the average body mass index (BMI) was 27.3 ( $\pm 3.4$ ) kg/m<sup>2</sup>. Age, BMI and PDS score are shown separately for each treatment group in **Table 1**. At baseline, the whole sample showed a PDS score of 31.5 ( $\pm 10.5$ ) and after treatment a score of 28.1 ( $\pm 13.2$ ), demonstrating a significant decrease over time [F(1, 28)=6.39,  $p < .05$ ]. There was no significant main effect of group [F(1, 28) < 1, n.s.] or group x time interaction.

Parameters of the TNF- $\alpha$  system: **Table 1** also shows the serum concentrations of TNF- $\alpha$  and its soluble receptors sTNF-R p55 and sTNF-R p75 separately for both treatment groups. Regarding the whole group, there was a significant increase over time with regard to TNF- $\alpha$  [F(1, 29)=81.03,  $p < .001$ ], contrasting with a significant decrease to its receptors sTNF-R p55 [F(1, 31)=8.94,  $p < .01$ ] and sTNF-R p75 [F(1, 28)=4.82,  $p < .05$ ]. No significant main effect of group or group x time interaction was detected for TNF- $\alpha$ , sTNF-R p55 and sTNF-R p75 serum concentrations [all: F(1, 28-31) < 1, n.s.].

----- Insert **Table 1** here. -----

Influence of antidepressant medication: We compared patients taking antidepressants (N=16) with those using homeopathic remedies or no psychotropic medication. No statistically significant differences were found for TNF- $\alpha$ , sTNF-R p55 and sTNF-R p75. In a consecutive ANCOVA controlling for medication all previously detected statistical effects remained significant: TNF- $\alpha$  [F(1, 28)=10.81,  $p < .01$ ]; sTNF-R p55 [F(1, 29)=5.41,  $p < .05$ ] and sTNF-R p75 [F(1, 26)=5.10,  $p < .05$ ]. We also calculated spearman rank correlations between the changes in the TNF- $\alpha$  system and the PDS scores. No statistically significant correlations between decrease in PDS score and changes in the parameters of the TNF- $\alpha$  system were found.



## Discussion

Both treatment groups showed a significant decrease in PTSD symptoms after treatment as measured by the PDS score. In addition, whereas TNF- $\alpha$  concentrations increased, sTNF-R p55 and sTNF-R p75 levels decreased significantly over time in the whole study sample. To our knowledge, this is the first study investigating possible changes within the TNF- $\alpha$  system during psychological treatment for PTSD. Therefore, the present investigation suggests that clinical improvement following PTSD treatment might influence the production or release of TNF- $\alpha$  and sTNF-Rs.

Changes of TNF- $\alpha$ , sTNF-R p55 and sTNF-R p75 levels during psychological treatment could theoretically be due to a degree of recovery from PTSD or represent an effect or side effect of psychotherapy. However, our previous study did neither show any correlation between serum levels of TNF- $\alpha$ , sTNF-R p55 or sTNF-R p75 and the PDS scores in this patient sample (Himmerich et al. 2015) nor any statistically significant difference of TNF- $\alpha$ , sTNF-R p55 or sTNF-R p75 serum levels of soldiers with PTSD compared to those without PTSD (Himmerich et al. 2016). Consistent with these findings, in the present study we did not find any statistically significant association between the decrease in the PDS score and the changes in the parameters of the TNF- $\alpha$  system. Therefore, it seems unlikely that TNF- $\alpha$ , sTNF-R p55 or sTNF-R p75 levels changed as a result of an improvement of PTSD symptoms.

As animal studies have shown that TNF- $\alpha$  production increases during stressful events (Krügel et al. 2014), one consideration may be that EMDR therapy, which includes imagination of a trauma, or being allocated to outpatient clinical management, instead of a perceived more favorable specific psychological treatment for PTSD (e.g. inpatient psychotherapy), could also lead to stress. Therefore, an increase of TNF- $\alpha$  production or release could be a side effect of psychotherapy or a result of patient disappointment.

From a psychopharmacological perspective, the increase of TNF- $\alpha$  production we observed is not surprising, since a number of effective psychopharmacological drugs, such as mirtazapine (Kraus et al. 2002), carbamazepine and lithium (Himmerich et al. 2005), clozapine and olanzapine (Kluge et al. 2009), have also been shown to lead to changes in the TNF- $\alpha$  system. TNF- $\alpha$  has been implicated in the development of autoimmune diseases (Ghezzi & Cerami 2005). For example, its elevation during lithium therapy has been thought to play a role in the appearance or exacerbation of psoriasis or hypothyroidism, a side effect of lithium therapy (Petersein et al. 2015). Increased production of TNF- $\alpha$  during lithium therapy is seen as an

advantage for patients suffering from human immunodeficiency virus (HIV) infection (Petersein et al. 2015). However, the effects of psychotherapy on the cytokine system and their consequences for the course of infectious diseases and autoimmune disorders have scarcely been investigated. While this may be an interesting question to arise from the results of the present study, our data should not be used to draw far-reaching conclusions in terms of a direct effect of psychotherapy on the immune system.

The changes in the TNF- $\alpha$  system observed could also be a consequence of psychotherapy leading to the intended effects of treatment, as short-term stress and activation of physiological parameters during psychotherapy could result in long-term improvement. This idea has already been considered in other areas of psychotherapy in terms of changes in cortisol production during stress. For example, in eating disorders, mirror confrontation leads to an increase in skin conductance and saliva cortisol concentration (Vocks et al. 2007). Such an increase in saliva cortisol has also been reported during in-vivo exposure of agoraphobic patients (Schumacher et al. 2014). Furthermore, basic research in humans and animals has shown that cortisol can enhance memory consolidation of new information, but impair memory retrieval of already stored information (de Quervain et al. 2009). On the basis of these known effects on memory processes, it has been proposed that cortisol enhances exposure therapy through two mechanisms: 1) cortisol-induced reduction of memory retrieval: an aversive cue is no longer followed by the usual, full-blown retrieval of fear memory and; 2) cortisol is known to enhance memory consolidation of new information and is assumed to enhance the storage of corrective experiences (de Quervain et al. 2011, Lass-Hennemann & Michael 2014). Therefore, cytokine activation during psychotherapy could also theoretically have favorable effects which are yet to be determined.

However, it may be that not psychotherapy itself, but rather behavioural consequences of psychotherapy or the behavioural changes associated with returning home after deployment have caused the observed alterations within the TNF- $\alpha$  system. Such changes could be due to nicotine or alcohol consumption, lifestyle, physical activity or diet. Unfortunately, we did not gather data on these factors longitudinally. Furthermore, the simple change of location and the consecutive adaptations within the immune system should also be taken into account when interpreting the present data.

The TNF- $\alpha$  parameters did not significantly differ between the inpatient psychotherapy group and the outpatient clinical management group. Therefore, inpatient psychotherapy (including

EMDR) does not seem to exert a specific influence on TNF- $\alpha$ , sTNF-R p55 and sTNF-R p75 serum concentrations. Rather, as changes were observed in both treatment groups, a non-specific effect of psychotherapy could have contributed. This is supported by studies in depressed patients showing that cognitive behavior therapy (Moreina et al. 2015) as well as dynamic psychotherapy (Del Grande da Silva et al. 2016) lead to changes in TNF- $\alpha$  production. Thus, psychotherapy may influence the TNF- $\alpha$  system, independently of the specific diagnosis or the specific psychotherapeutic approach. Given that several other types of psychiatric treatment including psychopharmacological drugs (Himmerich et al. 2005, Kraus et al. 2002), relaxation training (Koh et al. 2008) and electroconvulsive therapy (Rotter et al. 2013) modulate the TNF- $\alpha$  system, an influence of psychotherapy on these parameters is also conceivable. However, in the current study, we cannot rule out that the changes in TNF- $\alpha$ , sTNF-R p55 and sTNF-R p75 levels are a pure effect of time after deployment abroad. To investigate this thoroughly would require a control group suffering from combat-related PTSD receiving no treatment, which would have been ethically unjustifiable. Further longitudinal research into cytokine responses in relation to various stressors, emergence of disorders and during periods of treatment would likely be informative.

Even though certain antidepressants are known to influence cytokine production (Kraus et al. 2002), the use of antidepressants did not influence TNF- $\alpha$ , sTNF-R p55 and sTNF-R p75 levels in our sample. As the patients in our sample used different types of antidepressants, we could only compare patients taking antidepressants with those using no antidepressant medication. As some antidepressants, such as venlafaxine (Kraus et al. 2002), may not influence TNF- $\alpha$ , sTNF-R p55 and sTNF-R p75 levels, our investigation is not suitable to study the influence of antidepressants on cytokine production specifically.

A further limitation of this study is the small sample size of 38 patients in total, with 21 in the inpatient psychotherapy group. However, psychopharmacological agents, such as the antidepressant mirtazapine, the mood stabilizers lithium and carbamazepine and the antipsychotics olanzapine and clozapine, have been reported to influence the TNF- $\alpha$  system in studies with a comparable or smaller sample size (Kraus et al. 2002, Himmerich et al. 2005, Kluge et al. 2009).

Another limitation of the present investigation is that sTNF-R p55 or sTNF-R p75 serum levels in these soldiers were not measured prior to deployment abroad. Such a longitudinal study design starting prior to deployment abroad would have enabled more specific

conclusions about a possible connection between PTSD and parameters of the TNF- $\alpha$  system.

In addition, in the present study, we did not attempt to detect feigned PTSD or PTSD symptom exaggeration, in a standardized way, although measures for detecting malingering, such as specific scales of the Minnesota Multiphasic Personality Inventory-2 (MMPI-2), are available (Efendov et al. 2008). This issue might be specifically pertinent in soldiers because of eligibility for a state pension or other benefits if their PTSD is determined to be combat-related and treatment-resistant. Therefore, one could question the initial PTSD diagnosis of these patients. However, the patients were assessed by an experienced military psychiatrist and obvious malingering would have obviated their inclusion in the study.

In conclusion, to our knowledge, we performed the first study investigating the effect of psychiatric therapy and specifically inpatient psychotherapy including EMDR on serum levels of TNF- $\alpha$ , sTNF-R p55 or sTNF-R p75 in PTSD patients. The specific inpatient psychotherapy but also non-specific outpatient clinical management treatment reduced PTSD symptoms as measured by the PDS score and altered TNF- $\alpha$ , sTNF-R p55 and sTNF-R p75 concentrations. It seems to be most likely that these changes are attributable to non-specific psychotherapeutic effect or side effects. From a methodological view, further confirmatory studies should incorporate a longitudinal design starting at the time before the deployment abroad, include a control group without any treatment, have a larger sample size and should try to detect feigned PTSD as well as PTSD symptom exaggeration.

### **Conflict of interest**

The authors state that they do not have any conflicts of interest with regards to this article.

### **Acknowledgement**

The authors thank Wolfgang Wilfert for technical support. This work was financially supported by the Claussen-Simon-Foundation. This funding source did not have any influence on the study, on the analysis of data, or on writing of the present manuscript.

## References

- 1) Berthold-Losleben M & Himmerich H: The TNF-alpha system: functional aspects in depression, narcolepsy and psychopharmacology. *Curr Neuropharmacol* 2008; 6: 193-202.
- 2) Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Bankovic D, Arsenijevic N et al.: Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. *J Psychiatr Res* 2012; 46: 1421-6.
- 3) Borovcanin M, Jovanovic I, Radosavljevic G, Djukic Dejanovic S, Stefanovic V, Arsenijevic N et al.: Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response. *Schizophr Res* 2013; 147: 103-109.
- 4) Carswell EA, Old LJ, Kassel RL, Green S, Fiore N & Williamson B: An endotoxin-induced serum factor that causes necrosis of tumors. *Proc Natl Acad Sci USA* 1975; 72: 3666-70.
- 5) Chen T, Guo M, Gao Y, Chen F, Guo J, Liu T et al.: A comparative study on the levels of serum cytokines and cortisol among post-traumatic stress disorder patients of Li and Han ethnicities in Hainan. *Chin Med J* 2014; 127: 2771-4.
- 6) Del Grande da Silva G, Wiener CD, Barbosa LP, Gonçalves Araujo JM, Molina ML, San Martin P et al.: Pro-inflammatory cytokines and psychotherapy in depression: Results from a randomized clinical trial. *J Psychiatr Res* 2016; 75: 57-64.
- 7) De Kloet CS, Vermetten E, Geuze E, Kavelaars A, Heijnen CJ & Westenberg HG: Assessment of HPA-axis function in posttraumatic stress disorder: pharmacological and non-pharmacological challenge tests, a review. *J Psychiatr Res* 2006; 40: 550-67.
- 8) De Quervain DJ, Aerni A, Schelling G & Roozendaal B: Glucocorticoids and the regulation of memory in health and disease. *Front Neuroendocrinol* 2009; 30: 358–70
- 9) De Quervain DJ, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J et al.: Glucocorticoids enhance extinction-based psychotherapy. *Proc Natl Acad Sci USA* 2011; 108: 6621–5.
- 10) Efendov AA, Sellbom M & Bagby RM: The utility and comparative incremental validity of the MMPI-2 and Trauma Symptom Inventory validity scales in the detection of

- feigned PTSD. *Psychol Assess* 2008; 20: 317-26.
- 11) Foa EB: *Posttraumatic Stress Diagnostic Scale Manual*. National Computer Systems Inc, 1995.
  - 12) Ghezzi P & Cerami A: Tumor necrosis factor as a pharmacological target. *Mol. Biotechnol* 2005; 31: 239-44.
  - 13) Himmerich H, Koethe D, Schuld A, Yassouridis A & Pollmächer T. Plasma levels of leptin and endogenous immune modulators during treatment with carbamazepine or lithium. *Psychopharmacology* 2005; 179: 447-51.
  - 14) Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S et al.: Depression, comorbidities and the TNF-alpha system. *Eur Psychiatry* 2008; 23: 421-9.
  - 15) Himmerich H, Schönherr J, Fulda S, Sheldrick AJ, Bauer K & Sack U: Impact of antipsychotics on cytokine production in-vitro. *J Psychiatr Res* 2011; 45: 1358-65.
  - 16) Himmerich H, Bartsch S, Hamer H, Mergl R, Schönherr J, Petersein C et al.: Impact of mood stabilizers and antiepileptic drugs on cytokine production in-vitro. *J Psychiatr Res* 2013; 47: 1751-9.
  - 17) Himmerich H, Willmund GD, Zimmermann P, Wolf JE, Bühler AH, Holdt LM et al.: Serum concentrations of TNF- $\alpha$ , sTNF-R p55 and p75 and post-traumatic stress in German soldiers. *Eur Cytokine Netw* 2015; 26: 57-60.
  - 18) Himmerich H, Wolf JE, Zimmermann P, Bühler AH, Holdt LM, Teupser D et al.: Serum Concentrations of Tumor Necrosis Factor- $\alpha$  and its Soluble Receptors in Soldiers with and Without Combat-related Posttraumatic Stress Disorder: Influence of Age and Body Mass Index. *Chin Med J* 2016; 129: 751-2.
  - 19) Jergović M, Bendelja K, Savić Mlakar A, Vojvoda V, Aberle N, Jovanovic T et al.: Circulating levels of hormones, lipids, and immune mediators in post-traumatic stress disorder - a 3-month follow-up study. *Front Psychiatry* 2015; 6: 49.
  - 20) Kluge M, Schuld A, Schacht A, Himmerich H, Dalal MA, Wehmeier PM et al.: Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever. *Psychoneuroendocrinology* 2009; 34: 118-28.

- 21) Koh KB, Lee Y, Beyn KM, Chu SH & Kim DM. Counter-stress effects of relaxation on proinflammatory and anti-inflammatory cytokines. *Brain Behav Immun* 2008; 22: 1130-7.
- 22) Kraus T, Haack M, Schuld A, Hinze-Selch D, Koethe D & Pollmächer T: Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. *Pharmacopsychiatry* 2002; 35: 220-5.
- 23) Krügel U, Fischer J, Bauer K, Sack U & Himmerich H: The impact of social isolation on immunological parameters in rats. *Arch Toxicol* 2014; 88: 853-5.
- 24) Lass-Hennemann J & Michael T. Endogenous cortisol levels influence exposure therapy in spider phobia. *Behav Res Ther* 2014; 60: 39-45.
- 25) Lindqvist D, Wolkowitz OM, Mellon S, Yehuda R, Flory JD, Henn-Haase C et al.: Proinflammatory milieu in combat-related PTSD is independent of depression and early life stress. *Brain Behav Immun* 2014; 42: 81-8.
- 26) Maes M, Song C & Yirmiya R: Targeting IL-1 in depression. *Expert Opin Ther Targets* 2012; 16: 1097-112.
- 27) McCarthy S: Posttraumatic Stress Diagnostic Scale (PDS). *Occup Med* 2008; 58: 379.
- 28) Miller AH, Haroon E, Raison CL & Felger JC. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. *Depress Anxiety* 2013; 30: 297-306.
- 29) Moreira FP, Cardoso Tde A, Mondin TC, Souza LD, Silva R, Jansen K et al.: The effect of proinflammatory cytokines in Cognitive Behavioral Therapy. *J Neuroimmunol* 2015; 285: 143-6.
- 30) Müller N, Weidinger E, Leitner B & Schwarz MJ: The role of inflammation in schizophrenia. *Front Neurosci* 2015; 9:372.
- 31) Munzer A, Sack U, Mergl R, Schönherr J, Petersein C, Bartsch S et al.: Impact of antidepressants on cytokine production of depressed patients in vitro. *Toxins* 2013; 5: 2227-40.
- 32) Pandey GN, Ren X, Rizavi HS & Zhang H: Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients.

- Schizophr Res 2015; 164: 193-8.
- 33) Petersein C, Sack U, Mergl R, Schönherr J, Schmidt FM, Lichtblau N et al.: Impact of lithium alone and in combination with antidepressants on cytokine production in vitro. *J Neural Transm* 2015; 122:109-22.
- 34) Rotter A, Biermann T, Stark C, Decker A, Demling J, Zimmermann R et al.: Changes of cytokine profiles during electroconvulsive therapy in patients with major depression. *J ECT* 2013; 29: 162-9.
- 35) Schmidt FM, Lichtblau N, Minkwitz J, Chittka T, Thormann J, Kirkby KC et al.: Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. *J Psychiatr Res* 2014; 55: 29-34.
- 36) Schumacher S, Gaudlitz K, Plag J, Miller R, Kirschbaum C, Fehm L et al.: Who is stressed? A pilot study of salivary cortisol and alpha-amylase concentrations in agoraphobic patients and their novice therapists undergoing in vivo exposure. *Psychoneuroendocrinology*. 2014;49: 280-9
- 37) Turhan L, Batmaz S, Kocbiyik S & Soygur AH: The role of tumour necrosis factor alpha and soluble tumour necrosis factor alpha receptors in the symptomatology of schizophrenia. *Nord J Psychiatry* 2016; 70: 342-50.
- 38) Vocks S, Legenbauer T, Wächter A, Wucherer M & Kosfelder J: What happens in the course of body exposure? Emotional, cognitive, and physiological reactions to mirror confrontation in eating disorders. *J Psychosom Res* 2007; 62: 231-9.



**Table 1:** Mean and standard deviation (SD) of the descriptive variables age and body mass index (BMI) as well as the outcome parameters Post-traumatic Stress Diagnostic Scale (PDS) score and serum concentrations of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and its soluble receptors (sTNF-R) p55 and p75 separately for both treatment groups at baseline and after treatment. Regarding the whole group, there was a significant increase in TNF- $\alpha$  serum concentration ( $p < .01$ ), but a significant decrease of sTNF-R p55 ( $p < .05$ ) and sTNF-R p75 ( $p < .05$ ) levels during the treatment period. Significant group differences in TNF- $\alpha$  parameters (inpatient vs. outpatient therapy) were not detected.

		Inpatient psychotherapy (N=21)				Outpatient clinical management (N=17)			
		<i>Mean</i>	<i>SD</i>			<i>Mean</i>	<i>SD</i>		
<b>Descriptive Variables</b>	Age [years]	28.0	7.62			28.8	3.40		
	BMI [kg/m <sup>2</sup> ]	27.8	2.03			26.9	4.13		
<b>Outcome Parameters</b>		<b>Baseline</b>		<b>After treatment</b>		<b>Baseline</b>		<b>After treatment</b>	
		<i>Mean</i>	<i>SD</i>	<i>Mean</i>	<i>SD</i>	<i>Mean</i>	<i>SD</i>	<i>Mean</i>	<i>SD</i>
	PDS score	29.0	12.0	24.8	12.9	33.6	8.9	30.9	13.2
	TNF- $\alpha$ [pg/mL]	5.2	4.48	17.6	6.91	7.4	5.16	18.9	6.84
	sTNF-R p55 [pg/mL]	405.2	110.7	356.0	114.5	400.8	137.8	319.4	116.9
	sTNF-R p75 [pg/mL]	1412.0	439.8	1212	359.4	1250.0	375.2	1154	471.7